PEN2: Metformin’s new partner at lysosome

Kei Sakamoto; Niels Jessen

doi:10.1038/s41422-022-00661-7

PEN2: Metformin’s new partner at lysosome

Kei Sakamoto^*, Niels Jessen

^*Corresponding author af dette arbejde

Sakamoto Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

3 Citationer (Scopus)

Abstract

Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.

Originalsprog	Engelsk
Tidsskrift	Cell Research
Vol/bind	32
Sider (fra-til)	507-508
ISSN	1001-0602
DOI	https://doi.org/10.1038/s41422-022-00661-7
Status	Udgivet - 2022

Adgang til dokumentet

10.1038/s41422-022-00661-7

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160082/pdf/41422_2022_Article_661.pdfLicens: Andet

Citationsformater

@article{1df9e75236ec4fd68d2ab330c68235eb,

title = "PEN2: Metformin{\textquoteright}s new partner at lysosome",

abstract = "Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.",

author = "Kei Sakamoto and Niels Jessen",

year = "2022",

doi = "10.1038/s41422-022-00661-7",

language = "English",

volume = "32",

pages = "507--508",

journal = "Cell Research",

issn = "1001-0602",

publisher = "nature publishing group",

}

TY - JOUR

T1 - PEN2

T2 - Metformin’s new partner at lysosome

AU - Sakamoto, Kei

AU - Jessen, Niels

PY - 2022

Y1 - 2022

N2 - Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.

AB - Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.

U2 - 10.1038/s41422-022-00661-7

DO - 10.1038/s41422-022-00661-7

M3 - Journal article

C2 - 35418220

AN - SCOPUS:85129339624

VL - 32

SP - 507

EP - 508

JO - Cell Research

JF - Cell Research

SN - 1001-0602

ER -